| The role of cell signalling in the crosstalk between autophagy and apoptosis LA Booth, S Tavallai, HA Hamed, N Cruickshanks, P Dent Cellular signalling 26 (3), 549-555, 2014 | 349 | 2014 |
| GRP78/Dna K is a target for Nexavar/Stivarga/Votrient in the treatment of human malignancies, viral infections and bacterial diseases JL Roberts, M Tavallai, A Nourbakhsh, A Fidanza, T Cruz‐Luna, E Smith, ... Journal of cellular physiology 230 (10), 2552-2578, 2015 | 57 | 2015 |
| OSU‐03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood–Brain Barrier: Implications for Anti‐Cancer Therapies L Booth, JL Roberts, M Tavallai, A Nourbakhsh, J Chuckalovcak, J Carter, ... Journal of cellular physiology 230 (8), 1982-1998, 2015 | 53 | 2015 |
| Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic M Tavallai, L Booth, JL Roberts, A Poklepovic, P Dent Frontiers in oncology 6, 142, 2016 | 52 | 2016 |
| Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function L Booth, B Shuch, T Albers, JL Roberts, M Tavallai, S Proniuk, A Zukiwski, ... Oncotarget 7 (11), 12975, 2016 | 51 | 2016 |
| The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling L Booth, JL Roberts, M Tavallai, T Webb, D Leon, J Chen, WP McGuire, ... Oncotarget 7 (15), 19620, 2016 | 49 | 2016 |
| Expressed gene fusions as frequent drivers of poor outcomes in hormone receptor–positive breast cancer KJ Matissek, ML Onozato, S Sun, Z Zheng, A Schultz, J Lee, K Patel, ... Cancer discovery 8 (3), 336-353, 2018 | 41 | 2018 |
| Differential regulation of autophagy and cell viability by ceramide species N Cruickshanks, JL Roberts, MD Bareford, M Tavallai, A Poklepovic, ... Cancer biology & therapy 16 (5), 733-742, 2015 | 31 | 2015 |
| Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells GB Sajithlal, HA Hamed, N Cruickshanks, L Booth, S Tavallai, J Syed, ... Molecular Pharmacology 84 (4), 562-571, 2013 | 28 | 2013 |
| Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo L Booth, T Albers, JL Roberts, M Tavallai, A Poklepovic, IO Lebedyeva, ... Oncotarget 7 (26), 40398, 2016 | 24 | 2016 |
| [Pemetrexed+ Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling L Booth, JL Roberts, M Tavallai, J Chuckalovcak, DK Stringer, ... Oncotarget 7 (17), 23608, 2016 | 24 | 2016 |
| How can molecular abnormalities influence our clinical approach MJB W Wei, G Fulci, S Luffer, R Kumar, B Wu, M Tavallai, R T Bekele Annals of Oncology 28 (8), 2017 | 13 | 2017 |
| Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer ML Onozato, S Sun, Z Zheng, A Schultz, J Lee, K Patel, PL Jerevall, ... | | 2017 |
